Larry Dauer provided a tour de force on protection challenges in medicine today. Medical personnel are increasingly involved with traditional and novel uses of radiation and radioactive materials in medical practice. The use of CT examinations has skyrocketed over the years, increasing total population exposure. Challenges in the emergency room setting cannot be overstated (Linton et al. 2011; Sierzenski et al. 2013). Although rare, CT examinations have been administered incorrectly, and deterministic effects (e.g., hair loss) have been reported (Bogdanich 2010; Bogdanich and Ruiz 2010). Interventional procedures have resulted in ulcers and skin burns (ICRP 2000). Deterministic effects or tissue reactions are more frequent in the treatment of patients where very high doses are delivered to small volumes of tissue for the purpose of killing malignant cells. Collateral damage, unfortunately, includes damaging the good tissues along the way (NCRP 2011; ICRP 2012). Staff involved with interventional radiology receive the largest proportion of medical dose, and cumulative exposures sufficient to result in cataracts are being reported and at levels lower than previously supposed (ICRP 2000; Vano et al. 2013). Whether the current guidelines for dose to the lens should be lowered in the United States is currently being discussed, including stakeholder involvement. Regulations to minimize eye exposures could impact on the way some procedures are done and on how many certain providers could perform (e.g., cardiologists and interventional radiographers) in their work. NCRP limits for annual and cumulative effective dose (NCRP 1993) and for equivalent dose to the lens differ from those of ICRP (2007, 2012), and there is a need to update and reassess guidance in these areas. There is an expanding use of radioactive elements in medicine: diagnostic imaging, positron emission tomography (PET) imaging, multimodal imaging, nuclear medicine tracers and stress tests, and sentinel node and radiation seed location. The “brave new world” of nuclear medicine includes expanding uses of anti-matter (i.e., positron emitters). Positron emitters such as 89Zr require a cyclotron to produce, result in higher gamma energy emissions than most radionuclides in current use, and may impact the design of medical facilities. New types of treatment modalities, such as proton beam therapy, require new types of radiation protection programs and especially skilled physicists and engineers to operate. The present and future challenges include improved dosimetry to cope with new radiations (higher energy gamma rays, protons, neutrons), measuring lens dose, measuring extremity dose, recognizing and addressing the novel uses of a variety of radionuclides, and coping with the new technologies of cyclotrons, proton machines, and possibly carbon ion therapy in the future. The “old road is rapidly agin’ … The order is rapidly fadin’ … For the times they are a-changin’.” Changing times require changing minds!
Jim Brink discussed the extremely important need for dose tracking for patients. Such a system would be beneficial to the patient, the clinical practitioner, and perhaps to epidemiologists in the future who wish to correlate or include medical exposures in studies of cancer risk. The variability of patients (age, weight, life expectancy) and their treatments makes dose estimation difficult, and there is a need for common metrics of dose (effective dose, whole-body dose, organ dose, cumulative dose – preferably organ dose) and for how long (indefinitely to enable long-term follow-up). Most new CT machines include some measure of dose, which is a good first step. Tracking patient doses would also minimize unnecessary repeat examinations by avoiding, for example, needless double CT scans (Bogdanich and McGinty 2011). Tracking might be focused first in the areas of most use (e.g., the emergency room setting). The selection of types of examinations for patients based on diagnostic algorithms also might be standardized based on appropriateness criteria. A goal is to reduce the error in the use of radiation and also of contrast media. It is encouraging that the medical community has banded together to provide practical educational tools and advocacy to accelerate radiation protection for children and adults worldwide through the Image Gently™ and Image Wisely™ initiatives (Goske et al. 2010; Brink and Amis 2010), as well as increased awareness in emergency medicine (Linton et al. 2011; Sierzenski et al. 2013).
The diagnostic uses of radiation are with CT, nuclear medicine, radiography, and fluoroscopy. The American College of Radiology has supported a Dose Index Registry, which currently collects dose information for CT scans but will expand to other modalities and will start collecting data based on patient size (ACR 2011; Morin et al. 2011). Reference levels and achievable doses can provide guidance as to the optimal use of imaging procedures (NCRP 2012b). Patient size matters, and image quality as well as organ dose can be affected if suboptimal machine settings are used during scans (Israel et al. 2010; AAPM 2011). There are many, many publications on the possible future risk of cancer among patients receiving CT examinations (Berrington de González et al. 2009). However, there are few studies contrasting patient outcomes from the underlying condition requiring care with the possible future risk of radiation-induced cancer. Among young adults undergoing body CT examination, the risk of death from the underlying condition being evaluated was more than an order of magnitude greater than the theoretical future death from radiation-induced cancer (Zondervan et al. 2013). The patient’s underlying medical morbidity, rather than possible CT-induced cancer, was the dominant factor driving a potentially adverse outcome. Managing incidental findings on CT examination remains a challenging endeavor but is being addressed (Berland et al. 2010). Communicating radiation risks with patients and obtaining true informed consent continues to be a challenge (Dauer et al. 2011; Brink et al. 2012). Constant vigilance is required in the use of diagnostic imaging procedures, since the impact of multiple repeat examinations, even when clinically indicated, can result in organ doses that approach the range where epidemiologic investigation has revealed risk (Katz et al. 2006; Sodickson et al. 2009).
Lois Travis provided a marvelous overview of the risk of cancer and cardiovascular disease following radiation therapy for cancer patients (Travis et al. 2012; NCRP 2011). With the success of cancer treatments, patients are now living much longer and the risk for late effects has increased accordingly, not only for developing new second cancers, but also serious heart conditions. NCRP Report No. 170, prepared under the leadership of Lois Travis, provides a recent review including quantitative estimates of risk following curative therapies and examination of dose-response relationships (NCRP 2011). In 2007, there were 13.7 million survivors of first cancers in the United States, which indicates the future burden of and the continued need to evaluate late effects of therapy (Siegel et al. 2012). Children with cancer are one of the great treatment success stories of the past 50 y. Treatment has improved survival dramatically, and now many can live almost disease free, although not without the consequences of their curative therapies. Because children continue to grow after treatment and because of their long life expectancy, they are particularly susceptible to late effects, and constant monitoring and concern are warranted (Robison et al. 2009). One remarkable statistic is that the absolute number of new second cancers in a year is greater than the number of any single cancer diagnosed in that same year (i.e., greater than prostate, greater than lung, greater than breast)! Further, the burden for diagnostic and therapeutic radiation services will only increase as the baby boomers start requiring substantial medical care due to their age and longevity. NCRP Report No. 170 (NCRP 2011) makes several recommendations, including the long-term, large-scale follow-up of cancer survivors to allow development of guidelines for prevention and intervention.
Error prevention in radiotherapy is particularly important because the tolerances are so small. A mistake when treating a cancer patient can be pretty serious. If the delivered dose is too large or inappropriately distributed, then serious tissue damage can result. If the dose is too low, the consequence is also serious, because there will not be enough malignant cells killed to cure the patient. Another theme that came up repeatedly in all sessions was genetic susceptibility (underlying predisposition) to radiation-induced cancer and noncancer diseases. Individual susceptibility is an important issue, and it would be wonderful to be able to profile patients as to the effectiveness of different therapies and the likelihood of future adverse events. It’s not possible now, but the explosion of research on inherited mutated genes and polymorphism bodes well for the future, at least in some limited circumstances. NCRP might consider another summary of genetic susceptibility and the interaction with radiation, as well as with other cofactors such as smoking and lifestyle. An update of the medical doses in Report No. 160 (NCRP 2009) might be considered given the rapidity of change across the country. There are different treatment modalities, different ways in which patients are diagnosed, and different ways in which patients are monitored and screened. NCRP is in tune with the need for electronic record systems and the tracking of individual radiation doses.
The third session addressed worker exposures within U.S. Department of Energy (DOE) weapons and nuclear industry facilities, after nuclear reactor accidents, and associated with military activities, especially the humanitarian assistance provided during the Fukushima natural disaster and nuclear accident. Presentations were made by scientists from NCI; the National Institute for Occupational Safety and Health (NIOSH); and the Defense Threat Reduction Agency (DTRA), U.S. Department of Defense (DOD).
Jim Neton (NIOSH) described the methods used to estimate radiation doses to DOE workers covered by the Energy Employees’ Occupational Illness Compensation Program Act (EEOICPA 2000; Neton et al. 2008). EEOICPA was created by Congress in October 2000 and provides compensation for adverse health effects assumed to be related to work involved in the production of nuclear weapons. The program covers work performed for DOE (or its predecessor agencies). Part B of the Act provides monetary benefits for workers who developed cancer. A probability of causation [PC (or more correctly termed the assigned share)] interactive radioepidemiological computer program is used to establish eligibility for an award. There are about 750,000 former workers from more than 200 facilities who may be eligible for compensation under EEOICPA. To support the dose reconstruction of almost 40,000 workers to date, NIOSH has collected literally millions of pieces of supporting information. Because the doses are estimated with “claimant favorable” methods, they are not directly appropriate for epidemiological uses without modification. As of September 2012, 28.8% of 9,072 claims received compensation [i.e., the computed PC was greater than 50% (or to be more technically correct, compensation was awarded when the upper 99th percentile of the probability distribution accounting for uncertainty exceeded 50%)]. Recently the uncertainties associated with the PC computations were evaluated by NCRP (2012a; Preston et al. 2013). One limitation of the current approach is that tying the award to the uncertainty distribution inadvertently awards uncertainty. For example, cases of lymphoma and malignant melanoma, which have uncertain associations with radiation, are more likely to be compensated than cases of stomach cancer and breast cancer, which are more strongly associated with radiation (UNSCEAR 2008). The most common cancers for which compensation claims were made were of the lung, prostate, and skin, comprising together >50% of the claims. Missed (unknown) dose for intakes of insoluble actinides (e.g., uranium, plutonium, americium, and others) were estimated and incorporated into the dose reconstruction; the incorporation of these missed doses often produced PCs that resulted in compensation. Cancers of organs that do not concentrate internal radionuclides (e.g., prostate or brain) have low compensation rates unless there were high external doses. Relatively low doses for cancers with high excess relative risk per sievert coefficients (e.g., nonchronic lymphocytic leukemia) can result in compensation. The July 2009 issue of Health Physics (Vol. 95, No. 1) is entirely devoted to the NIOSH Dose Reconstruction Program.
Andre Bouville (NCI) summarized worker exposures at early nuclear plants and fuel reprocessing facilities in the United States (Hanford in Washington state) and in the former Soviet Union (Mayak). He also discussed worker exposures following the nuclear reactor accidents at Windscale, Three Mile Island, Chernobyl, and Fukushima. The Hanford Works (1944+) produced plutonium for military uses with nine nuclear reactors and five plutonium processing plants. The counterpart in Russia was the Mayak complex (1948+), with five nuclear reactors and one radiochemical plant. The average doses from external radiation during the early operations were 100 to 1,000 times greater among Mayak workers compared with Hanford workers. For example, in 1949 the average doses were 0.65, 950, and 400 mSv for the Hanford, Mayak Reactor, and Mayak radiochemical workers, respectively.
The Windscale accident in the United Kingdom occurred in 1957 and involved 471 workers. No worker received >50 mSv, and no health effects were reported or are anticipated. In 1959, an accident occurred at the Santa Susana Field Laboratory in California when a sodium reactor experiment, which had produced electricity for the city of Moorpark, California, in 1957, experienced a core melting (Boice et al. 2011). Worker exposure during the accident and cleanup activities appeared minimal with mean career doses <20 mSv, although doses were not described per se for the accident workers. No health effects have been reported. The Three Mile Island accident in Pennsylvania occurred in 1979 and involved thousands of workers over time. No worker received >50 mSv and no health effects were reported or are anticipated. The Chernobyl nuclear rector accident in the former Soviet Union occurred in 1986 and is the most severe nuclear reactor accident that has ever occurred in the nuclear power industry (UNSCEAR 2011). Hundreds of emergency workers were involved in stopping the burning reactor and getting it under control. Doses were so high (up to 16 Gy) for 134 emergency workers that they developed acute radiation sickness, and 28 died within a few months of the accident. Over 500,000 workers were involved in the recovery/cleanup efforts through 1990, and the mean recorded dose was 117 mGy. Studies are ongoing with complex dose reconstruction schemes but are challenging because doses were not recorded for all workers. Proxy interviews are being conducted, the radiation fields were complex, and time and location parameters were not known accurately. The Fukushima accident in Japan occurred in 2013 and involved over 25,000 workers, both Tokyo Electric Power Company and contract workers. The average dose was 12 mSv, and at least six workers received >250 mSv. The high effective doses were related to the inhalation of radioactive iodine during the early phase of the accident and not to whole body external exposures. Fewer than 200 workers received above 100 mSv external dose.
Many lessons are continuing to be learned from these accidents that are relevant to protection activities in the 21st century. For Fukushima, these include but are not limited to:
* assessing the importance of internal exposures;
* managing emergency crises;
* protecting rescuers and volunteers;
* responding with medical aid;
* justifying necessary but disruptive protective actions;
* transiting from an emergency to an existing situation;
* rehabilitating evacuated areas;
* restricting individual doses to members of the public;
* caring for infants and children;
* categorizing public exposures due to an accident;
* considering pregnant women and their fetuses or embryos;
* monitoring public protection;
* coping with contaminated territories, rubble, and residues and consumer products;
* fostering the sharing of information; and
* recognizing the importance of psychological consequences (González et al. 2013).
Paul Blake (DTRA) provided a unique overview of radiation exposure of U.S. military personnel. The extensive military program of radiation protection in the United States has received little recognition and has an interesting history. One of the first uses of radiation in the military was during the Spanish-American War in 1898, where diagnostic x-ray units were deployed just 3 y after x-rays were discovered by Roentgen (Borden 1900). The U.S. military maintains occupational radiation exposure records from 1945 to the present on 2.3 million unique individuals. About 2% (or 70,000) of the 1.4 million active duty military personnel, 1.3 million National Guard and reserves, and 0.7 million civilian employees are monitored annually for radiation exposure. Radioepidemiological studies have been conducted over the years and include atomic veterans (Caldwell 1983; Watanabe et al. 1995; Johnson et al. 1996; Dalager et al. 2000; Thaul et al. 2000), workers at shipyards involved with the overhaul of nuclear powered ships (Fry et al. 1996; Matanoski et al. 2008), submariners who received nasopharyngeal radium treatments (Kang et al. 2000), nuclear submariners (Charpentier et al. 1993; Friedman-Jimenez et al. 2003), and veterans of the Gulf War exposed to depleted uranium (McDiarmid et al. 2013).
It was impressive to learn that the U.S. Navy has more operational nuclear reactors, 104, than there are commercial nuclear power reactors in the United States. The Naval vessels include 71 nuclear submarines and 11 nuclear aircraft carriers. The responsible organization, Naval Reactors, is consistently recognized for its record of excellence with no reactor accidents after 151 million miles of sea travel. Occupational exposures for vessel operators have been and remain historically low. The majority of radiation exposure occurs at four Navy shipyards that maintain nuclear powered vessels.
After the 2011 Japanese earthquake and tsunami, the U.S. Department of Defense (DOD) launched a large-scale humanitarian effort to help the Japanese called “Operation Tomodachi,” involving 24,000 U.S. service members, 189 aircraft, and 24 Naval ships. Although personnel were not in the direct vicinity of the Fukushima reactors, the radiological releases potentially exposed 53,000 DOD-affiliated individuals on shore, and 17,000 individuals on ships. DOD conducted extensive environmental monitoring and estimated exposures for 70,000 individuals. This registry is unique in many ways, including the inclusion of military spouses of personnel stationed at military bases throughout Japan and their children. To date, the estimates of radiation dose are tiny, much less than received by natural background radiation in a month, and as such will not result in any observable health effects. DOD has five repositories of radiation exposure:
* Operation Tomodachi Registry;
* Army Dosimetry Center;
* Naval Dosimetry Center;
* Air Force Dosimetry Center; and
* DTRA’s Nuclear Test Personnel Review.
The Nuclear Test Personnel Review provides the foundation for compensating atomic veterans for presumptive and nonpresumptive radiogenic diseases. The military compensation program covers ~220,000 participants at above-ground weapons tests and the 200,000 early military entrants to Hiroshima and Nagasaki after the 1945 detonations. Presumptive diseases are defined by Congress, so that the veteran (with DTRA assistance) just has to prove that he or she was present at a nuclear test or in Japan after the bombings to receive compensation. Nonpresumptive diseases require complex dose reconstruction and probability of causation computations similar to that described for the DOE worker compensation program. NCRP and Vanderbilt University are directing an epidemiologic follow-up of 115,000 participants at eight above ground test series at the Nevada Test Site and the Pacific Proving Grounds with dose reconstructions based on best estimates of organ dose and not high-sided ones used for compensation purposes (Boice 2012b).
The final session covered radiation exposures to the general public. Highlighted were the continued studies of Japanese atomic bomb survivors, the studies of cancer rates in populations living near nuclear facilities and following nuclear reactor accidents, and the studies of populations living on the Techa River and exposed to radioactive wastes from the Mayak Reactor facilities in Russia.
Harry Cullings (Radiation Effects Research Foundation, Japan) discussed the latest results of the study of Japanese atomic bomb survivors that has continued since 1946 when President Harry S Truman approved the creation of the Atomic Bomb Casualty Commission “to undertake a long range, continuing study of the biological and medical effects of the atomic bomb on man.” Now directed by the Radiation Effects Research Foundation, the Life Span Study (LSS) is the longest running epidemiologic study in history, with the 1948 Framingham Heart Study a close second (Scheindlin 2010)! Like “Old Man River,” the LSS just keeps rollin’ along and after all these years still has more to offer, in particular learning about the lifetime risk of radiation exposure following childhood and adolescent exposures that occurred in 1945 (Ozasa et al. 2012). The study of Japanese atomic bomb survivors has provided important information on radiation risks used for guidance in setting radiation protection guidelines (NCRP 1993; ICRP 2007). Included among the many important scientific findings is that the children of atomic bomb survivors are not at increased risk of heritable affects; childhood exposures carry more of a cancer burden than exposures in utero; a single exposure in 1945 apparently increases cancer risk for life; women are more susceptible than men to radiogenic disease; some cancers are not clearly associated with cancer (e.g., chronic lymphocytic leukemia, prostate cancer, testicular cancer, cervical cancer, and lymphoma, among others); myelodysplastic disease may occur some 40–50 y after exposure; age at exposure strongly influences future cancer risk, with children being at higher risk than adults for many but not all cancers (Mettler et al. 2013; UNSCEAR 2013); surgically-defined cataracts continue to occur with an estimated threshold dose of ~500 mGy; and other noncancers such as heart disease and stroke may be occurring at doses lower than previously assumed (UNSCEAR 2008). Remarkably, all of these conclusions are based on relatively small numbers of excess cases: 537 excess solid cancers out of 10,928 could be statistically attributed to radiation, as could 94 excess leukemias out of 312, and 353 noncancer (cardiovascular and cerebrovascular deaths) out of 35,685. About half of the cohort of 93,741 survivors (including 86,671 in-city members of the LSS with estimated doses) remains alive, so there’s more to be learned. Interestingly, it was estimated that on average, about 10 y of life were lost per gray among women and 15 y of life were lost per gray among men. Acute effects of high radiation doses were not a focus of the LSS, but 500 mGy was estimated as a rough threshold for the most sensitive acute symptoms such as nausea. Additionally, there is renewed interest in the so-called “black rain” fallout (Kerr et al. 2013). “Black rain” refers to the color of the rain that fell in some sections of Hiroshima, but it does not necessarily imply that radioactive fission products were present in the rain. Fallout has been assumed to be minimal because the detonation was in the sky and not on ground, and because of the prevailing winds, individual dose estimates from residual radioactivity are not currently included in the LSS dosimetry systems. Because of the important role the LSS study plays in radiation protection schemes worldwide, there is continued evaluation of all sources of radiation (gamma radiation, neutrons, and fallout) to improve as needed estimates of doses to individuals.
There are some circumstances of the LSS that limit the strength of the generalization that can be made with respect to U.S. and other healthy populations. First and foremost is that the exposure occurred in a fraction of a second (i.e., it was brief), whereas most exposure situations today are chronic and occur gradually over time. The Japanese population was exposed in 1945, survived a nuclear detonation, lived in a war-torn country, and was confronted with malnutrition, deprivation, infection, and other overriding health and psychosocial concerns. Thus, the population is not very similar to healthy populations today experiencing occupational, environmental, and medical exposures. Mortality follow-up did not occur until 1950, or 5 y after exposure, and cancer incidence follow-up did not occur until 1957 or 13 y after exposure. Because the exposure occurred in a single year, 1945, there are uncertainties associated with the confounding effects of birth cohort on baseline disease rates. That is, age at exposure and birth cohort are perfectly correlated, so that factors associated with birth cohort (such as smoking habits, diet, and viral infections) could affect the pattern of risk with age at exposure but cannot be accounted for in the analysis. The existing epidemiologic data on human health effects (ICRP 2007; NCRP 2012a) thus have been transformed and transported, modulated and manipulated, and there is a potential procrustean problem (i.e., forced conformity to a somewhat arbitrary set of statistical models) (Mettler et al. 2013). Recall that Procrustes was the mythological highwayman who cut off (or stretched on a rack) the legs of travelers so they would fit his iron bed (i.e., he forced conformity to an arbitrary set of conditions). Nonetheless, the LSS is the single most important radiation study by far and will remain so for the immediate future.
Next was Bruce Napier (Pacific Northwest National Laboratory), who provided a comprehensive overview of the history of the Mayak Production Association in central Russia, covering its operations, radionuclide releases, and associated doses to the public. Environmental releases from Mayak exposed people living in the nearby city of Ozersk, along the Techa River where radioactive wastes were released, and in the area downwind of Mayak, which was called the East Urals Radioactive Trace following the 1957 “Kyshtym Explosion,” a chemical explosion of a liquid radioactive waste storage tank. Each of these cohorts is providing information on protracted exposures for which the magnitude of cancer risk from low dose and low dose-rate radiation exposure remains uncertain. The Techa River cohort of 29,730 is particularly informative (Kossenko et al. 2005; Krestinina et al. 2007; Schonfeld et al. 2013). The population lived along the Techa River between 1950–1960 and was exposed to radioactive and chemical wastes released into the river from Mayak. The exposure was to both external gamma radiation and internal 90Sr, 137Cs, and other radionuclides. Although fraught with uncertainties in estimating exposures to the population living along the banks of the Techa River, individualized doses have been reconstructed based on the Techa River Dosimetry System (Degteva et al. 2000, 2006). It was estimated that about 2% (or 50) of the 2,303 solid cancer deaths were statistically associated with the radiation exposure. While the study supports an increased risk of solid cancer mortality following protracted radiation exposure from the Techa River contamination, the wide confidence intervals around the estimates of risk reflect “the challenges of quantifying and describing the shape of the dose-response relationship in the low dose range” (Schonfeld et al. 2013).
As with all observational studies, the Techa River Cohort Study is not without limitations, which weaken the strength of conclusions that can be made. The study suffers from uncertainties in dose reconstructions, incomplete population identification, potential screening bias, concomitant high dose medical screening exposures, losses to follow-up, and uncertain quality and completeness of outcome ascertainment (NCRP 2012a). The methodological limitations are notable in comparison with other cohort studies of exposed populations: 22.7% of the Techa River population was lost to follow-up, mainly due to migration out of the catchment area; cause of death was missing for 9% of those known to have died; less than half of the solid cancer cases were histologically confirmed; and 20% of cancers were either ascertained solely on the basis of clinical notes or the method of diagnosis was not specified clearly (Krestinina et al. 2007; Schonfeld et al. 2013). Further, the small number of excess cancers, only 50 overall, limited the evaluation of site-specific risk estimates so that only total cancers could be evaluated for dose response. Such analyses of all solid cancers combined, however, do not take into account heterogeneity of the magnitude and/or the shapes of different dose-response curves across tumor sites. Thus, informative comparisons with other population studies with different underlying baseline rates and confounding influences are not straightforward. Nonetheless, the Techa River studies including the Techa River Cohort (30,000 individuals), the Techa River Offspring Cohort (31,000 individuals), and the East Urals Radioactive Trace Cohort (18,000 evacuated; 8,000 resident) are continuing to provide important information on the level of risks following chronic exposure to relatively high levels of radiation following environmental contamination.
Because there are few prospective studies of children exposed in utero and followed into adulthood, a recent cohort study of over 8,000 children of female workers at the Mayak Nuclear Facility is noteworthy (Schonfeld et al. 2012). The in utero gamma-ray doses were large (mean 54.5 mGy; max ~800 mGy) and accumulated throughout the pregnancy, and thus not received briefly at one point in time. The exposures were measured by film badges and not estimated—a notable strength and uniqueness of the study. There was no evidence that prenatal gamma radiation received during pregnancy increased the risk of solid cancer or leukemia mortality up to 60 y of follow-up. The small number of cancers, however, limited the precision of the study, and thus the negative findings were consistent in a statistical sense with the positive observations of 2,452 children born to Japanese atomic-bomb survivors who received comparable doses in utero (Preston et al. 2008). Although speculative, the absence of a radiation effect among the offspring of Mayak female workers is also consistent with the possibility that chronic exposures during pregnancy are less effective in causing cancer later in life than if the exposure were received acutely, as was the case for the children of atomic bomb survivors exposed in utero.
Daniel O. Stram (University of Southern California) provided an overview and extremely well balanced evaluation of the recent National Academy of Sciences (NAS) feasibility study on investigating cancer occurrence in populations residing near nuclear facilities in the United States (NA/NAS 2012). Based on historical radiation release data from commercial nuclear facilities, the population doses would be tiny (maximum 100–200 µSv y−1) and the statistical power of any study to find effects at such low dose would be extremely low to nonexistent. It is clear, however, that these studies are of societal important to provide reassurance to the populations living around nuclear facilities and, of course, to identify any unforeseen circumstances resulting in clusterings of cancer of etiologic and scientific import. The U.K. Sellafield Nuclear Facility cluster (in the village of Seascale), for example, generated much research that generally concluded that leukemia in children was not related to radiation releases but may have been related to a rare response to a common infectious agent due to population mixing (Doll 1999). The NA/NAS committee recommended that a limited pilot study of seven facilities in six states be initiated, focusing on childhood leukemia incidence occurring within smaller geographical units that were used in the previous NCI study (Jablon et al. 1991) (i.e., census tracts rather than counties). Other limitations of the previous NCI ecological study included follow-up only through 1984. Absence of information on population doses, use of mortality rather than incidence of cancer, the fact that the size of the county may be too large a geographical area to detect localized increases in cancer rates, the plethora of comparisons that were made increased the likelihood that chance played a role in highlighting areas with seemingly high or low cancer rates, and unknown factors associated with migration and selection of residence and occupation could contribute to cancer occurrence in these areas. Nonetheless, the large NCI survey included more than 900,000 cancer deaths in 113 counties in the United States containing or adjacent to 62 nuclear facilities that were compared with 1,800,000 cancer deaths in control counties with similar population and socioeconomic characteristics (Jablon et al. 1991). There was no evidence that mortality for any cancer, including childhood leukemia, was higher in counties with nuclear reactors than in the control counties. For childhood leukemia, the relative risk in the study counties versus their controls before start-up was 1.08, and it was 1.03 (i.e., lower) after plant start-up.
Other than the Seascale cluster, the most notable cluster of childhood leukemia was around the Krümmel Nuclear Power Plant in Northern Germany (Kaatsch et al. 2008). The study was extended to include all nuclear power plants in Germany, and the large, very well conducted, investigation found a positive association with proximity to nuclear power plants in Germany. Noting that the population exposures from emissions from nuclear power plants are much lower than average doses from background and medical sources, the authors commented that, “The reported findings were thus not to be expected under radiation biological and epidemiological considerations.” One methodological concern surrounding the extended German study was the inclusion of Krümmel Nuclear Power Plant data, which generated the hypothesis. Removal of the Krümmel cluster from the combined analysis apparently reduced the finding for childhood leukemia to nonstatistical significance (COMARE 2011; Kinlen 2011a, 2011b). The most recent comprehensive evaluation by the British around their nuclear facilities actually found a negative correlation with distance (i.e., the closer the residence to the nuclear facility, the lower the risk of childhood leukemia) (Bithell et al. 2008). Further, the recent COMARE (2011) report, which reviewed all studies up through 2011 (and should be required reading for anyone interested in this area), concluded that “there is no evidence to support the view that there is an increased risk of childhood leukemia and other cancers in the vicinity of NPPs (nuclear power plants) due to radiation effects.” Nonetheless, if public concerns about safety outweigh other priorities and resources are available, an update of the NCI study could very well provide reassurance and, as in the past, be deemed worth doing as providing a benefit to society.
Maureen Hatch (NCI) provided a marvelous finale to the NCRP 2013 Annual Meeting. She discussed effects on the public following nuclear reactor accidents and echoed previous speakers in noting that psychosocial outcomes will likely emerge as the most significant and widespread health effect—and one that until recently has not been well recognized (Bromet 2012). Risk perception plays a role and points to the importance of risk communication and radiation education (Table 3). Jimmy Buffett, in Volcano Lyrics, exemplified the problem in that despite the essential absence of population exposure in 1979 after the Three Mile Island Reactor accident, he “Don’t want to land in the Three Mile Island; Don’t want to see my skin aglow (no no no).” When I returned from visiting the damaged nuclear Fukushima Reactor in 2011, my wife told friends not “to get me angry,” alluding to the possibility that I would transform into something like the green Hulk as when Dr. Banner got mad. Perception and reality—will ever the twain be met? Hopefully we can do better with education, sound understanding, and start with the young generation.
Other than psychosocial disorders, thyroid cancer following exposures to children living near Chernobyl in 1986 is the only convincing late effect from the nuclear accident (UNSCEAR 2011). Over 5,000 thyroid cancers have been detected, but fortunately, fewer than 10 deaths have been reported. Problems in quantifying the risk following radioactive iodine exposures include the ecological nature of many studies, inadequate assessment of thyroid dose, effects of intense screening, and special surveillance of the heavily exposed and dietary deficiencies of stable iodine (IARC 2001). Perhaps the most methodologically sound study is the NCI-Ukraine study that addressed many of the deficiencies in prior studies (Brenner et al. 2011). The estimated excess relative risk at 1 Gy of 1.91 (relative risk of 2.91 at 1 Gy) following protracted exposure to radioiodines during childhood (131I has an 8 d half-life) can be contrasted with the excess relative risk at 1 Gy of 7.7 following acute exposure to external radiation (Ron et al. 1995). Although statistically compatible, the data suggest that radioactive iodines may be four times less effective than acute exposures to external radiation. This lower effectiveness is consistent with studies of thyroid nodularities after fallout from Semipalatinsk nuclear detonations, which concluded that internal exposures were three times less effective than external exposures (Land et al. 2008), and with the comprehensive studies of thyroid disorders following the Hanford 131I releases in the 1940s and 1950s, which found little evidence for a dose response for thyroid cancer, nodules, or thyroid hormone levels despite estimated mean thyroid doses of 0.17 Gy (maximum 2.8 Gy) (Davis et al. 2004).
An intriguing finding in several of the Chernobyl studies is the possible influence of dietary stable iodine on radiation-related thyroid cancer. The Ukraine-Russian-Belarus areas were inland, and diets deficient in iodine were not uncommon, resulting in endemic goiter. In one case-control study, the risk from the exposure to radioiodines appeared concentrated among children residing in severe iodine-deficient areas (i.e., where the radiation risk was three times higher than the risk observed in children residing in the areas of less severe iodine deficiency) (Cardis et al. 2005). The thyroid glands living in areas of iodine deficiency are likely more active and undergo more cellular proliferation and growth than in areas of iodine sufficiency, and it may be that this enhanced cellular activity is related to the enhanced risk observed. If the elevated radiation risk reflects an interaction with a dysfunctional thyroid gland, it would temper generalizations to other areas in the world with dietary iodine sufficiency (Boice 2005), such as around Fukushima where the diets have a surplus of stable iodine due to high fish and seaweed consumption. The child’s thyroid gland proliferates more rapidly than the adult gland, and it is thought that this rapid cell growth is the primary reason why radiation effects are so apparent after exposures in childhood and not among adults. Given the influence of stable iodine on subsequent risk of radiation-related thyroid cancer, there may be a need to reassess guidance on the use of potassium iodide during accident circumstances.
Table 6 and Table 7 provide snapshots of the Annual Meeting and ways forward into the 21st century. Radiation is in the public eye because of Fukushima, CT examinations, airport screenings, and possible terrorist attacks. Nuclear power may be on the resurgence due to concerns with greenhouse gases and projected growth in electrical demands. Because of the increasing uses of radiation, the increases in population exposures, and the increasing knowledge of radiation effects, constant vigilance is needed to keep up with the changing times. Psychosocial disorders associated with the inappropriate (but real) fear of radiation need to be recognized as a radiation detriment. Radiation risk communication, radiation education, and communication must improve at all levels: to members of the public, the media, other scientists, and radiation professionals (Table 3). Stakeholders must continue to be involved in all radiation protection initiatives (Table 2). Finally, we are at a crisis in that the baby boomer radiation professionals are depleting at a rapid rate, and there are few in the pipeline to fill the current and looming need. NCRP has initiated WARP—Where Are the Radiation Professionals? as an attempt to rejuvenate the pipeline before the trickle is at its last drop. Meetings were held in July 2013 with government agencies, military, private sector, universities, White House representatives, and societies to develop a coordinated and national action plan. Stay tuned, and please help! “If we don’t keep swimmin’ (Disney’s Nemo),” “we’ll sink (Dylan).”
AAPM. Size-specific dose estimates (SSDE) in pediatric and adult body CT examinations. College Park, MD: American Association of Physicists in Medicine; Working Group Report #204; 2011. Available at www.aapm.org/pubs/reports/RPT_204.pdf
. Accessed 27 July 2013.
Akiba S. Epidemiological studies of Fukushima residents exposed to ionising radiation from the Fukushima Daiichi Nuclear Power Plant prefecture—a preliminary review of current plans. J Radiol Protect 32: 1–10; 2012. Available at www.ncbi.nlm.nih.gov/pubmed/22327057
. Accessed 19 September 2012.
Berland LL, Silverman SG, Gore RM, Mayo-Smith WW, Megibow AJ, Yee J, Brink JA, Baker ME, Federle MP, Foley WD, Francis IR, Herts BR, Israel GM, Krinsky G, Platt JF, Shuman WP, Taylor AJ. Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J Am Coll Radiol 7: 754–773; 2010.
Berrington de González A, Mahesh M, Kim KP, Bhargavan M, Lewis R, Mettler F, Land C. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med 169: 2071–2077; 2009.
Bithell JF, Keegan TJ, Kroll ME, Murphy MF, Vincent TJ. Childhood leukaemia near British nuclear installations: methodological issues and recent results. Radiat Protect Dosim 132: 191–187; 2008.
Boice JD Jr. Radiation-induced thyroid cancer—what’s new? J Natl Cancer Inst 97: 703–705; 2005.
Boice JD Jr, Cohen SS, Mumma MT, Ellis ED, Eckerman KF, Leggett RW, Boecker BB, Brill AB, Henderson BE. Updated mortality analysis of radiation workers at Rocketdyne (Atomics International), 1948–2008. Radiat Res 176: 244–258; 2011.
Borden WC. The use of the Röntgen ray by the Medical Department of the United States Army in the War with Spain (1898). Washington, DC: U.S. Government Printing Office; 1900.
Brenner AV, Tronko MD, Hatch M, Bogdanova TI, Oliynik VA, Lubin JH, Zablotska LB, Tereschenko VP, McConnell RJ, Zamotaeva GA, O’Kane P, Bouville AC, Chaykovskaya LV, Greenebaum E, Paster IP, Shpak VM, Ron E. I-131 dose response for incident thyroid cancers in Ukraine related to the Chornobyl accident. Environ Health Perspect 119: 933–939; 2011.
Brink JA, Amis ES Jr. Image Wisely: a campaign to increase awareness about adult radiation protection. Radiol 257: 601–602; 2010.
Brink JA, Goske MJ, Patti JA. Informed decision making trumps informed consent for medical imaging with ionizing radiation. Radiol 262: 11–14; 2012.
Caldwell GG, Kelley D, Zack M, Falk H, Heath CW Jr. Mortality and cancer frequency among military nuclear test (SMOKY) participants, 1957 through 1979. JAMA 250: 620–624; 1983.
Cardis E, Kesminiene A, Ivanov V, Malakhova I, Shibata Y, Khrouch V, Drozdovitch V, Maceika E, Zvonova I, Vlassov O, Bouville A, Goulko G, Hoshi M, Abrosimov A, Anoshko J, Astakhova L, Chekin S, Demidchik E, Galanti R, Ito M, Korobova E, Lushnikov E, Maksioutov M, Masyakin V, Nerovnia A, Parshin V, Parshkov E, Piliptsevich N, Pinchera A, Polyakov S, Shabeka N, Suonio E, Tenet V, Tsyb A, Yamashita S, Williams D. Risk of thyroid cancer after exposure to 131
I in childhood. J Natl Cancer Inst 97: 724–732; 2005.
Charpentier P, Ostfeld AM, Hadjimichael OC, Hester R. The mortality of US nuclear submariners, 1969-1982. J Occup Med 35: 501–509; 1993. Erratum in: J Occup Med 35:949; 1993.
Chen SY, Tenforde TS. Optimizing decision making for late-phase recovery one year after the Fukushima nuclear accident. J Radiol Prot 32: 191–192; 2012. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22674029
. Accessed 10 February 2013.
Cherry JD, Liu B, Frost JL, Lemere CA, Williams JP, Olschowka JA, O’Banion MK. Galactic cosmic radiation leads to cognitive impairment and increased aβ plaque accumulation in a mouse model of Alzheimer’s disease. PLoS One 7 (12); 2012.
COMARE. Further consideration of the incidence of childhood leukaemia around nuclear power plants in Great Britain. London: Public Health England; Committee on Medical Aspects of Radiation in the Environment, Fourteenth Report; 2011.
Covello VT. Risk communication, radiation, and radiological emergencies: strategies, tools, and techniques. Health Phys 101: 511–530; 2011.
Dalager NA, Kang HK, Mahan CM. Cancer mortality among the highest exposed U.S. atmospheric nuclear test participants. J Occup Environ Med 42: 798–805; 2000. Available at www.ncbi.nlm.nih.gov/pubmed/1095381
. Accessed 11 November 2012.
Dauer LT. Exposed medical staff: challenges, available tools, and opportunities for improvement. Health Phys 106: 217–224; 2014.
Dauer LT, Thornton RH, Hay JL, Balter R, Williamson MJ, St Germain J. Fears, feelings, and facts: interactively communicating benefits and risks of medical radiation with patients. Am J Roentgenol 196: 756–761; 2011.
Davis S, Kopecky KJ, Hamilton TE, Onstad LHanford Thyroid Disease Study Team. Thyroid neoplasia, autoimmune thyroiditis, and hypothyroidism in persons exposed to iodine-131 from the Hanford Nuclear Site. JAMA 292: 2600–2613; 2004.
Degteva MO, Vorobiova MI, Kozheurov VP, Tolstykh EI, Anspaugh LR, Napier BA. Dose reconstruction system for the exposed population living along the Techa River. Health Phys 78: 542–554; 2000.
Degteva MO, Vorobiova MI, Tolstykh EI, Shagina NB, Shishkina EA, Anspaugh LR, Napier BA, Bougrov NG, Shved VA, Tokareva EE. Development of an improved dose reconstruction system for the Techa River population affected by the operation of the Mayak Production Association. Radiat Res 166: 255–270; 2006.
Doll R. The Seascale cluster: a probable explanation. Br J Cancer 81: 3–5; 1999.
EEOICPA. Energy Employees Occupational Illness Compensation Program Act of 2000. Washington, DC: U.S. Government Printing Office; Public Law 106-398 (October 30), 114 Stat. 1654; 2000.
Friedman-Jimenez G, Kato I, Afanasyeva Y, Shore R. Mortality of nuclear submariners in the U.S. Navy. Abstract 317. Abstracts of the 36th annual meeting of the Society for Epidemiologic Research. Atlanta, Georgia, USA. June 11–14, 2003. Am J Epidemio 157 (11 Suppl): S80; 2003.
Fry SA, Dupree EA, Sipe AH, Seiler DL, Wallace PW. A study of mortality and morbidity among persons occupationally exposed to ≥50 mSv in a year: phase I, mortality through 1984. Appl Occup Environ Hyg 11: 334–343; 1996. Available at www.tandfonline.com/doi/abs/10.1080/1047322X.1996.10389333
. Accessed 1 January 2013.
Gilbert ES. Ionising radiation and cancer risks: what have we learned from epidemiology? Int J Radiat Biol 85: 467–482; 2009.
González AJ, Akashi M, Boice JD Jr, Chino M, Homma T, Ishigure N, Kai M, Kusumi S, Lee J-K, Menzel H-G, Niwa O, Sakai K, Weiss W, Yamashita S, Yonekura Y. Radiological protection issues arising during and after the Fukushima nuclear reactor accident. J Radiol Protect 33: 497–571; 2013.
Goske MJ, Applegate KE, Bell C, Boylan J, Bulas D, Butler P, Callahan MJ, Coley BD, Farley S, Frush DP, McElveny C, Hernanz-Schulman M, Johnson ND, Kaste SC, Morrison G, Strauss KJ. Image Gently: providing practical educational tools and advocacy to accelerate radiation protection for children worldwide. Semin Ultrasound CT MR 31: 57–63; 2010.
IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Ionizing radiation, part 2: some internally deposited radionuclides. Lyon, France: International Agency for Research on Cancer; 2001.
ICRP. Avoidance of radiation injuries from medical interventional procedures. New York: Elsevier; International Commission on Radiological Protection; Ann ICRP 30: 7–67; 2000.
ICRP. 2007 recommendations of the International Commission on Radiological Protection. New York: Elsevier; International Commission on Radiological Protection; ICRP Publication 103; Ann ICRP 37 (2–4): 1–332; 2007. Available at www.icrp.org/publication.asp?id=ICRP%20Publication%20103
. Accessed 07 October 2012.
ICRP. ICRP statement on tissue reactions/early and late effects of radiation in normal tissues and organs—threshold doses for tissue reactions in a radiation protection context. New York: Elsevier; International Commission on Radiological Protection; ICRP Publication 118; Ann ICRP 41 (1/2); 2012. Available at www.icrp.org/publication.asp?id=ICRP%20Publication%20118
. Accessed 19 September 2012.
Israel GM, Cicchiello L, Brink J, Huda W. Patient size and radiation exposure in thoracic, pelvic, and abdominal CT examinations performed with automatic exposure control. Am J Roentgenol 195: 1342–1346; 2010.
Iwanaga M, Hsu WL, Soda M, Takasaki Y, Tawara M, Joh T, Amenomori T, Yamamura M, Yoshida Y, Koba T, Miyazaki Y, Matsuo T, Preston DL, Suyama A, Kodama K, Tomonaga M. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol 29: 428–434; 2011.
Jablon S, Hrubec Z, Boice JD Jr. Cancer in populations living near nuclear facilities. A survey of mortality nationwide and incidence in two states. JAMA 265: 1403–1408; 1991.
Johnson JC, Thaul S, Page WF, Crawford H. Mortality of veteran participants in the CROSSROADS nuclear test. Washington, DC: National Academies Press; 1996. Available at www.nap.edu/openbook.php?isbn=0309055962
. Accessed 11 November 2012.
Kaatsch P, Spix C, Schulze-Rath R, Schmiedel S, Blettner M. Leukaemia in young children living in the vicinity of German nuclear power plants. Int J Cancer 122: 721–726; 2008.
Kang HK, Bullman TA, Mahan CM. A mortality follow-up study of WW II submariners who received nasopharyngeal radium irradiation treatment. Am J Ind Med 38: 441–446; 2000.
Katz SI, Saluja S, Brink JA, Forman HP. Radiation dose associated with unenhanced CT for suspected renal colic: impact of repetitive studies. Am J Roentgenol 186: 1120–1124; 2006.
Kerr GD, Egbert SD, Al-Nabulsi I, Beck HL, Cullings HM, Endo S, Hoshi M, Imanaka T, Kaul DC, Maruyama S, Reeves GI, Ruehm W, Sakaguchi A, Simon SL, Spriggs GD, Stram DO, Tonda T, Weiss JF, Weitz RL, Young RW. Workshop report on atomic bomb dosimetry-RESIDUAL radiation exposure: recent research and suggestions for future studies. Health Phys 105: 140–149; 2013.
Kinlen L. Childhood leukaemia, nuclear sites, and population mixing. Br J Cancer 104: 12–18; 2011a.
Kinlen L. A German storm affecting Britain: childhood leukaemia and nuclear power plants. J Radiol Protect 31: 279–284; 2011b.
Kossenko MM, Thomas TL, Akleyev AV, Krestinina LY, Startsev NV, Vyushkova OV, Zhidkova CM, Hoffman DA, Preston DL, Davis F, Ron E. The Techa River cohort: study design and follow-up methods. Radiat Res 164: 591–601; 2005.
Krestinina LY, Davis F, Ostroumova E, Epifanova S, Degteva M, Preston D, Akleyev A. Solid cancer incidence and low-dose-rate radiation exposures in the Techa River cohort: 1956 2002. Int J Epidemiol 36: 1038–1046; 2007.
Land CE, Zhumadilov Z, Gusev BI, Hartshorne MH, Wiest PW, Woodward PW, Crooks LA, Luckyanov NK, Fillmore CM, Carr Z, Abisheva G, Beck HL, Bouville A, Langer J, Weinstock R, Gordeev KI, Shinkarev S, Simon SL. Ultrasound-detected thyroid nodule prevalence and radiation dose from fallout. Radiat Res 169: 373–383; 2008.
Linton O, Tenforde TS, Amis ES, Sierzenski P. Summary of workshop on CT in emergency medicine: ensuring appropriate use. J Am Coll Radiol 8: 325–329; 2011.
Locke PA. Communication of radiation benefits and risks in decision making: some lessons learned. Health Phys 101: 626–629; 2011.
Matanoski GM, Tonascia JA, Correa-Villaseñor A, Yates KC, Fink N, Elliott E, Sanders B, Lantry D. Cancer risks and low-level radiation in U.S. shipyard workers. J Radiat Res 49: 83–91; 2008.
McDiarmid MA, Gaitens JM, Hines S, Breyer R, Wong-You-Cheong JJ, Engelhardt SM, Oliver M, Gucer P, Kane R, Cernich A, Kaup B, Hoover D, Gaspari AA, Liu J, Harberts E, Brown L, Centeno JA, Gray PJ, Xu H, Squibb KS. The Gulf War depleted uranium cohort at 20 years: bioassay results and novel approaches to fragment surveillance. Health Phys 104: 347–361; 2013.
Mettler FA Jr, Bhargavan M, Faulkner K, Gilley DB, Gray JE, Ibbott GS, Lipoti JA, Mahesh M, McCrohan JL, Stabin MG, Thomadsen BR, Yoshizumi TT. Radiologic and nuclear medicine studies in the United States and worldwide: frequency, radiation dose, and comparison with other radiation sources—1950–2007. Radiol 253: 520–531; 2009.
Mettler FA Jr, Constine LS, Nosske D, Shore RE, Ninth annual Warren K. Sinclair keynote address—effects of childhood exposure: an issue from computed tomorgraphy scans to Fukushima. Proceedings of the forty-eighth annual meeting of the National Council on Radiation Protection and Measurements. Health Phys 105: 424–429; 2013.
Morin RL, Coombs LP, Chatfield MB. ACR dose index registry. J Am Coll Radiol 8: 288–291; 2011.
NA/NAS. Analysis of cancer risks in populations near nuclear facilities: phase I. Washington, DC: National Academies Press; National Academies/National Academy of Sciences; 2012.
NASA. Evaluation of research approaches to CNS risks from space radiation. Washington, DC: National Aeronautics and Space Administration; Space Radiation Ad Hoc Expert Panel on CNS Risks; 2012.
NCRP. Recommendations on limits for exposure to ionizing radiation. Bethesda, MD: National Council on Radiation Protection and Measurements; NCRP Report No. 91; 1987.
NCRP. Limitation of exposure to ionizing radiation. Bethesda, MD: National Council on Radiation Protection and Measurements; NCRP Report No. 116; 1993. Available at www.ncrppublications.org/Reports/116
. Accessed 24 July 2013.
NCRP. Ionizing radiation exposure of the population of the United States. Bethesda, MD: National Council on Radiation Protection and Measurements; NCRP Report No. 160; 2009. Available at www.ncrppublications.org/Reports/160
. Accessed 19 September 2012.
NCRP. Second primary cancers and cardiovascular disease after radiation therapy. Bethesda, MD: National Council on Radiation Protection and Measurements; NCRP Report No. 170; 2011. Available at www.ncrppublications.org/Reports/170
. Accessed 19 September 2012.
NCRP. Uncertainties in the estimation of radiation risks and probability of disease causation. Bethesda, MD: National Council on Radiation Protection and Measurements; NCRP Report No. 171; 2012a. Available at www.ncrppublications.org/Reports/171
. Accessed 19 September 2012.
NCRP. Reference levels and achievable doses in medical and dental imaging: recommendations for the United States. Bethesda, MD: National Council on Radiation Protection and Measurements; NCRP Report No. 172; 2012b. Available at www.ncrppublications.org/Reports/172
. Accessed 24 July 2013.
Neton JW, Howard J, Elliott LJ. Radiation dose reconstruction program of the National Institute for Occupational Safety and Health: overview. Health Phys 95: 6–13; 2008. Available at www.ncbi.nlm.nih.gov/pubmed/18545024
. Accessed 19 September 2012.
Ozasa K, Shimizu Y, Suyama A, Kasagi F, Soda M, Grant EJ, Sakata R, Sugiyama H, Kodama K. Studies of the mortality of atomic bomb survivors, Report 14, 1950–2003: an overview of cancer and noncancer diseases. Radiat Res 177: 229–243; 2012.
Preston DL, Cullings H, Suyama A, Funamoto S, Nishi N, Soda M, Mabuchi K, Kodama K, Kasagi F, Shore RE. Solid cancer incidence in atomic bomb survivors exposed in utero or as young children. J Natl Cancer Inst 100: 428–436; 2008.
Preston RJ, Boice JD Jr, Brill AB, Chakraborty R, Conolly R, Hoffman FO, Hornung RW, Kocher DC, Land CE, Shore RE, Woloshak GE. Uncertainties in estimating health risks associated with exposure to ionising radiation. J Radiol Protect 33: 573–588; 2013.
Robison LL, Armstrong GT, Boice JD, Chow EJ, Davies SM, Donaldson SS, Green DM, Hammond S, Meadows AT, Mertens AC, Mulvihill JJ, Nathan PC, Neglia JP, Packer RJ, Rajaraman P, Sklar CA, Stovall M, Strong LC, Yasui Y, Zeltzer LK. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol27: 2308–2318; 2009.
Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice JD Jr. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 141: 259–277; 1995.
Scheindlin S. Studies that keep rolling along: longitudinal analyses trade intervention for observations of change. Mol Interv 10: 190–196; 2010.
Schonfeld SJ, Tsareva YV, Preston DL, Okatenko PV, Gilbert ES, Ron E, Sokolnikov ME, Koshurnikova NA. Cancer mortality following in utero exposure among offspring of female Mayak Worker Cohort members. Radiat Res 178: 160–165; 2012.
Schonfeld SJ, Krestinina LY, Epifanova S, Degteva MO, Akleyev AV, Preston DL. Solid cancer mortality in the Techa River Cohort (1950–2007). Radiat Res 179: 183–189; 2013.
Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62: 220–241; 2012. Erratum in: CA Cancer J Clin 62:348; 2012.
Sierzenski PR, Linton OW, Amis ES Jr, Courtney DM, Larson PA, Mahesh M, Novelline RA, Frush DP, Mettler FA, Timins JK, Tenforde TS, Boice JD Jr, Brink JA, Bushberg JT, Schauer DA. Applications of Justification and Optimization in Medical Imaging: Examples of Clinical Guidance for Computed Tomography Use in Emergency Medicine. Ann Emerg Med 2013 Oct 10 [Epub ahead of print].
Signorello LB, Mulvihill JJ, Green DM, Munro HM, Stovall M, Weathers RE, Mertens AC, Whitton JA, Robison LL, Boice JD Jr. Stillbirth and neonatal death in relation to radiation exposure before conception: a retrospective cohort study. Lancet 376: 624–630; 2010.
Signorello LB, Mulvihill JJ, Green DM, Munro HM, Stovall M, Weathers RE, Mertens AC, Whitton JA, Robison LL, Boice JD Jr. Congenital anomalies in the children of cancer survivors: a report from the childhood cancer survivor study. J Clin Oncol 30: 239–245; 2012.
Sodickson A, Baeyens PF, Andriole KP, Prevedello LM, Nawfel RD, Hanson R, Khorasani R. Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults. Radiol 251: 175–184; 2009.
Thaul S, Page WF, Crawford H, O’Maonaigh HCommittee to Study the Mortality of Military Personnel Present at Atmospheric Tests of Nuclear Weapons. The five series study: mortality of military participants in U.S. nuclear weapons tests. Washington, DC: National Academies Press; 2000. Available at www.nap.edu/catalog.php?record_id=9697
. Accessed 11 November 2012.
Till JE, Grogan HA, Mohler HJ, Rocco JR, Rood AS, Mohler SS. An integrated approach to data management, risk assessment, and decision making. Health Phys 102: 367–377; 2012.
Travis LB, Ng AK, Allan JM, Pui C-H, Kennedy AR, Xu XG, Purdy JA, Applegate K, Yahalom J, Constine LS, Gilbert ES, Boice JD Jr. Second cancers and cardiovascular disease following radiotherapy (Commentary). J Natl Cancer Inst 104: 1–14; 2012.
UNSCEAR. Effects of ionizing radiation, UNSCEAR 2006 report. Scientific Annex A, Epidemiological studies of radiation and cancer. Vol I. New York: United Nations; United Nations Scientific Committee on the Effects of Atomic Radiation; 2008.
UNSCEAR. Scientific annex D, Health effects due to radiation from the Chernobyl accident. In: Sources and effects of ionizing radiation, UNSCEAR 2008 report, vol II. New York: United Nations; 2011.
Vano E, Ohno K, Cousins C, Niwa O, Boice J. Radiation risks and radiation protection training for healthcare professionals: ICRP and the Fukushima experience. J Radiol Protect 31: 285–287; 2011.
Vano E, Kleiman NJ, Duran A, Romano-Miller M, Rehani MM. Radiation-associated lens opacities in catheterization personnel: results of a survey and direct assessments. J Vasc Interv Radiol 24: 197–204; 2013.
Yasumura S, Hosoya M, Yamashita S, Kamiya K, Abe M, Akashi M, Kodama K, Ozasa K. Fukushima Health Management Survey Group. Study protocol for the Fukushima Health Management Survey. J Epidemiol 22: 375–383; 2012. Available at www.ncbi.nlm.nih.gov/pubmed/22955043
. Accessed 10 February 2013.
Zondervan RL, Hahn PF, Sadow CA, Liu B, Lee SI. Body CT scanning in young adults: examination indications, patient outcomes, and risk of radiation-induced cancer. Radiol 267: 460–469; 2013.
National Council on Radiation Protection and Measurements; radiation dosimetry; radiation epidemiology; radiation protection
Supplemental Digital Content
© 2014 by the Health Physics Society